COMMUNIQUÉS West-GlobeNewswire

FluidForm Bio™ Announces Participation at Biotech Showcase and the 14th Annual LifeSci Partners Corporate Access Event

08/01/2025 - 22:12

WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will deliver a company [...]

NurExone Biologic Secures Master Cell Bank

08/01/2025 - 22:12

A Key Milestone for Therapeutic Exosome Production TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (" NurExone " or the " Company "), a [...]

Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue

08/01/2025 - 22:10

Announces Earnings Release Date SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and [...]

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

08/01/2025 - 22:05

WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living [...]

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08/01/2025 - 22:05

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

08/01/2025 - 22:05

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025 IND applications for initiating first-in-human studies for ZW209 and ZW1528 [...]

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

08/01/2025 - 22:05

Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024 Scott Huennekens Appointed to NeuroPace Board of Directors [...]

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

08/01/2025 - 22:05

FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08/01/2025 - 22:05

EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing [...]

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

08/01/2025 - 22:05

CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

08/01/2025 - 22:05

Châtillon, France, January 8 th , 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of [...]

DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3

08/01/2025 - 22:05

Châtillon, France, le 8 janvier (22 :15 CEST) 2025 DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3 Les données de l'étude EPITOPE OLE ( [...]

Calidi Biotherapeutics Announces Proposed Public Offering

08/01/2025 - 22:01

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]

Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients

08/01/2025 - 19:30

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, published in Nature [...]

InkSpace Imaging Receives FDA 510(k) Clearance for 1.5T 24-channel MR Coil for Siemens Healthineers

08/01/2025 - 19:00

PLEASANTON, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- InkSpace Imaging, a leader in MRI coil innovation, today announced that the United States (US) Food and Drug Administration (FDA) has cleared InkSpace Imaging’s next [...]

X-tosis to Present at Seed Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference

08/01/2025 - 18:57

Company to Present Breakthrough Research Approach for a New Generation of Neurodegenerative Therapeutics GAINESVILLE, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- X-tosis , Inc., a pre-clinical biotech company transforming [...]

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

08/01/2025 - 18:30

As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") ( [...]

iTeos présentera ses travaux lors de la 43e conférence annuelle sur la santé de J.P. Morgan

08/01/2025 - 18:26

WATERTOWN, Massachusetts et GOSSELIES, Belgique, 08 janv. 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

08/01/2025 - 18:00

Jilin, China, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing [...]